New container developed for the needs of cell
and gene therapy (CGT) primary packaging to replace
cryopreservation bags with a fracture resistant, rigid construction
built for both manual use and closed-system automation.
BOTHELL,
Wash., May 29, 2024 /PRNewswire/ -- BioLife
Solutions, Inc. (NASDAQ: BLFS), a leading supplier of
bioproduction tools and services for the cell and gene therapy
(CGT) and broader biopharma markets, today announced the
introduction of the CryoCase, an addition to its CellSeal product
line.
"Particulates in drug product is a
growing problem that we believe can be reduced with better primary
containers."
Expected to be released to CGT developers in August, the
CryoCase is available for demonstration at this week's ISCT event
in Vancouver, Canada. Early
product evaluators stated that the CryoCase's volume versatility,
rigid and protective structure, and fill and retrieval port
designs, allows for easy integration with their current systems
generating improved throughput and streamlined procedures.
The CryoCase is the first ever cryo-compatible rigid container
designed for closed-system fill and retrieval for larger volumes of
fluid (<75mL). The container is transparent, enabling improved
end user compliance with USP 790, USP 1790, and other international
visible inspection methods, and manufactured under strict
environmental and processing controls designed to limit common
sources of particulates in single-use disposable manufacturing.
Early user testing has shown comparable cell viability and
recovery for multiple cell types compared to storage in existing
bags and drop testing in a frozen state demonstrates high
resistance to leaks or fractures. Initial testing indicates that
the CryoCase may materially reduce or eliminate particulates
inherent in cryopreservation bags.
"Particulates in reagent manufacturing and final drug product is
a growing problem that we believe can be reduced with better
primary containers and true, closed-system approaches to CGT
manufacturing," stated Todd Berard,
Chief Marketing Officer. "The CryoCase is compatible with various
downstream processing systems including our Signata CT-5, and we
believe it can reduce overall risks and costs involved in creating
and distributing these lifesaving therapies."
CryoCase samples are now available for testing. Contact your
BioLife Solutions representative for more information.
About BioLife Solutions
BioLife Solutions is a leading
supplier of class-defining bioproduction tools and services for the
cell and gene therapy (CGT) and broader biopharma markets. Our
expertise facilitates the commercialization of new therapies by
supplying solutions that maintain the health and function of
biologic materials during collection, development, storage, and
distribution. For more information, please visit
www.biolifesolutions.com or follow BioLife on LinkedIn and X.
Media & Investor Relations
At the Company
Troy Wichterman
Chief Financial Officer
(425) 402-1400
twichterman@biolifesolutions.com
Investors
LHA Investor Relations
Jody Cain
(310) 691-7100
jcain@lhai.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-introduces-the-cellseal-cryocase-at-international-society-for-cell--gene-therapies-isct-conference-in-vancouver-302157508.html
SOURCE BioLife Solutions, Inc.